Floatz logo
Floatz Rating
CCC52/100
Confidence
Indicative
v0.2
Sponsor
Nykode Therapeutics ASA
Modality
UNKNOWN
Development Phase
Phase 1/2
Status
Dormant
Evidence ledger · v0.2

Clinical Evidence

Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
37Moderate confidence
Detailed axis rationale is planned and will be published soon.
TrialPhaseStatusNPrimary endpointReadout
NCT03548467CT.gov
A Study to Evaluate Safety and Efficacy of Multiple Dosing With VB10.NEO and Bempegaldesleukin (NKTR-214) Immunotherapy in Patients With Locally Advanced or Metastatic Cancer
—Completed———

Competitive Position

Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Moderate confidence
Detailed axis rationale is planned and will be published soon.

Same indication · Soft Tissue Neoplasm

AssetSponsorPhaseRating
vb10.neo (this asset)Nykode Therapeutics ASAP1/2CCC · 52
Gamma1 Heavy Chain Humanized (1-448) [Vh (Homo Sapiens Ighv3-15*07 (86.9%)--(Ighd) -Ighj1*01(90.9%), Cdr-Imgt [8.10.9] (26-33.51-60.99-107))(1-118) -Homo Sapiens Ighg1*01 (100%), G1M17,1 Ch1K120, Ch3 D12, L14 (Ch1 K120 (215) (119-216),Hinge 1-15 (217-231), Ch2 (232-341), Ch3 D12 (357), L14 (359) (342-446), Chs (447-448)) (119-448)], (221-220')-Disulfide With Kappa Light Chain Humanized (1'-220') [V-Kappa (Homo Sapiens Igkv2-24*01 (90.0%)-Igkj2*01 (100%), Cdr-Imgt [11.3.10] (27-37.55-57.94-103)) (1'-113') -Homo Sapiens Igkc*01 (100%), Km3, A45.1 (159), V101 (197) (114'-220')]; Dimer (227-227'':230-230'')-Bisdisulfide, Produced In Chinese Hamster Ovary (Cho) Cells, Derived From The Cell Line Cho-K1, Glycoform AlfaAstraZenecaP2CCC
DurvalumabAstraZenecaP2CCC
Immunoglobulin G4, Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal Regn2810 Heavy Chain), Disulfide With Human Monoclonal Regn2810 .Kappa.-Chain, DimerAnkyra Therapeutics, IncP1CC
89-zr-dfo-star polyethylene glycolRobert Flavell, MD, PhDP1CC
TemsirolimusM.D. Anderson Cancer CenterP1CC
CetuximabM.D. Anderson Cancer CenterP1CC
Valproic AcidM.D. Anderson Cancer CenterP1CC
Tolododekin AlfaAnkyra Therapeutics, IncP1CC

+3 more in the Soft Tissue Neoplasm cohort

Scientific Foundation

Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR

Planned for methodology v0.2.

Development Feasibility

How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR

Planned for methodology v0.2.

Commercial Opportunity

Commercial prize: addressable population, unmet need, and the value case for the indication.
NR

Planned for methodology v0.2.

IP & Exclusivity

Exclusivity position, covering patent protection and freedom-to-operate runway.
NR

Planned for methodology v0.2.

Manufacturing & Supply

Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR

Planned for methodology v0.2.

Related assets

Citation

Floatz Terminal. vb10.neo in Soft Tissue Neoplasm. Methodology v0.2.
Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026.
Accessed July 14, 2026.
https://terminal.floatz.ai/assets/vb10neo-soft-tissue-neoplasm

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →